| 1 | of the arenavirus to | | | | | | | 3 | 0.51% |
| 2 | immune stimulation of the | | | | | | | 2 | 0.34% |
| 3 | arenavirus to fight cancer | | | | | | | 2 | 0.34% |
| 4 | unique immune stimulation of | | | | | | | 2 | 0.34% |
| 5 | cell types against primary | | | | | | | 2 | 0.34% |
| 6 | immune cell types against | | | | | | | 2 | 0.34% |
| 7 | relevant immune cell types | | | | | | | 2 | 0.34% |
| 8 | all relevant immune cell | | | | | | | 2 | 0.34% |
| 9 | activate all relevant immune | | | | | | | 2 | 0.34% |
| 10 | date on news around | | | | | | | 2 | 0.34% |
| 11 | to date on news | | | | | | | 2 | 0.34% |
| 12 | up to date on | | | | | | | 2 | 0.34% |
| 13 | stay up to date | | | | | | | 2 | 0.34% |
| 14 | the arenavirus to fight | | | | | | | 2 | 0.34% |
| 15 | make it an ideal | | | | | | | 1 | 0.17% |
| 16 | the mammarenavirus subcategory it | | | | | | | 1 | 0.17% |
| 17 | that make it an | | | | | | | 1 | 0.17% |
| 18 | candidate for a new | | | | | | | 1 | 0.17% |
| 19 | properties that make it | | | | | | | 1 | 0.17% |
| 20 | immunestimulatory properties that make | | | | | | | 1 | 0.17% |
| 21 | specific immunestimulatory properties that | | | | | | | 1 | 0.17% |
| 22 | has specific immunestimulatory properties | | | | | | | 1 | 0.17% |
| 23 | home the approach arenaviruses | | | | | | | 1 | 0.17% |
| 24 | to the mammarenavirus subcategory | | | | | | | 1 | 0.17% |
| 25 | belonging to the mammarenavirus | | | | | | | 1 | 0.17% |
| 26 | species belonging to the | | | | | | | 1 | 0.17% |
| 27 | viral species belonging to | | | | | | | 1 | 0.17% |
| 28 | studied viral species belonging | | | | | | | 1 | 0.17% |
| 29 | is one of the | | | | | | | 1 | 0.17% |
| 30 | lcmv is one of | | | | | | | 1 | 0.17% |
| 31 | host lcmv is one | | | | | | | 1 | 0.17% |
| 32 | respective host lcmv is | | | | | | | 1 | 0.17% |
| 33 | their respective host lcmv | | | | | | | 1 | 0.17% |
| 34 | to their respective host | | | | | | | 1 | 0.17% |
| 35 | one of the best | | | | | | | 1 | 0.17% |
| 36 | new treatment modality that | | | | | | | 1 | 0.17% |
| 37 | for a new treatment | | | | | | | 1 | 0.17% |
| 38 | foundation our scientific founders | | | | | | | 1 | 0.17% |
| 39 | mammarenaviruses that preferentially infect | | | | | | | 1 | 0.17% |
| 40 | of mammarenaviruses that preferentially | | | | | | | 1 | 0.17% |